NMIN is advancing research, innovation & training in nanomedicines to maintain Canada as the world leader in this revolutionary approach to treat & cure disease.
Nanomedicines, “smart” medicines that employ various forms of nanotechnology, are poised to have a revolutionary impact on drug development.
Nanomedicines will deliver drugs, such as anticancer drugs, more specifically to sites of disease to dramatically improve efficacy and reduce toxicity, and will also enable gene therapies employing RNA and DNA that have the potential to treat most human diseases. Diagnostics and imaging agents based on nanotechnology will allow us to detect disease earlier and monitor the effectiveness of therapy more accurately.
Nanomedicines have enormous potential to become the dominant medicines of the future.
The NanoMedicines Innovation Network (NMIN) is uniquely poised to reap this potential by building on the substantial achievements of Canadian scientists and entrepreneurs in nanomedicine.
NMIN researchers played material roles in the development of five of the 13 nanomedicines approved for systemic use by US FDA, Health Canada, and European EMA regulatory agencies, and they have established a vibrant nanomedicines R&D industry in Canada, consisting of over 20 companies with over 500 employees. These achievements allow Canada to claim the best record, worldwide, for the development of clinically approved nanomedicines.
NMIN’s vision: to establish and mobilize a network drawn from academia, industry, and not-for-profit research enterprises to maintain and improve Canada’s position as a global leader in developing next generation nanomedicines
The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brings investigators from universities across Canada—a multidisciplinary collective of physicists, engineers, chemists, biochemists, cell biologists, disease specialists, and clinicians—together with companies and not-for-profit research and granting institutions to expand and improve Canada’s position as world leader in nanomedicines R&D.
NMIN invests in projects aimed at developing new therapeutics and diagnostics. Particular efforts are made to conduct projects partnered with industry to ensure market impact.
NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
Equity, Diversity, and Inclusion (EDI) Commitment
NMIN is committed to recognizing and reducing systemic barriers and mitigating biases of all kinds to develop an inclusive network of nanomedicine and nanomedicine-related experts from across disciplines and sectors.
By integrating equity, diversity and inclusion into every process of the Network, this will exponentially strengthen the nanomedicines research and innovation community and the quality, relevance and impact of its research.
NMIN partners with industry, the healthcare system, and the government.
Partner organizations support the execution of research projects by providing infrastructure, core technology expertise, and proven approaches for selecting and advancing early drug candidates.
Business-oriented partners help design projects to ensure they will result in the creation of viable commercial products, and help NMIN to identify new potential partners or licensees.
All of NMIN’s proof-of-principle (PoP) projects—projects that aim to validate a diagnostic or to demonstrate a nanomedicine’s potential to treat a particular disease—are conducted in collaboration with industry partners, who bring cash and in-kind support. These partners are represented on the Project Management Committees and play an integral role in delineating PoP project plans.
The University of British Columbia (UBC) is the host institution of NMIN.
UBC and its Faculties of Medicine and Pharmaceutical Sciences, together with the Office of the Vice-President Research & Innovation of UBC, are providing NMIN with significant cash and in-kind support, and UBC’s Associate Vice President Research & Innovation serves on NMIN’s Board.
The nanomedicines field is a high-priority area for UBC in which it has a distinguished track record: UBC faculty have founded more than 10 nanomedicines spin-off companies leading to five nanomedicine products approved by the FDA and other regulatory agencies
2350 Health Sciences Mall, Room 5451
University of British Columbia
Vancouver, BC V6T 1Z3